125 related articles for article (PubMed ID: 21278576)
41. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
42. Duloxetine-related tardive dystonia and tardive dyskinesia: a case report.
Chen PY; Lin PY; Tien SC; Chang YY; Lee Y
Gen Hosp Psychiatry; 2010; 32(6):646.e9-646.e11. PubMed ID: 21112461
[TBL] [Abstract][Full Text] [Related]
43. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
44. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
Fava M; Wiltse C; Walker D; Brecht S; Chen A; Perahia D
J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
[TBL] [Abstract][Full Text] [Related]
45. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
Arnold LM; Meyers AL; Sunderajan P; Montano CB; Kass E; Trivedi M; Wohlreich MM
Ann Clin Psychiatry; 2008; 20(4):187-93. PubMed ID: 19034749
[TBL] [Abstract][Full Text] [Related]
46. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
47. Guideline-concordant antidepressant use among patients with major depressive disorder.
Chen SY; Hansen RA; Gaynes BN; Farley JF; Morrissey JP; Maciejewski ML
Gen Hosp Psychiatry; 2010; 32(4):360-7. PubMed ID: 20633739
[TBL] [Abstract][Full Text] [Related]
48. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
Ye W; Zhao Y; Robinson RL; Swindle RW
BMC Psychiatry; 2011 Jan; 11():19. PubMed ID: 21281479
[TBL] [Abstract][Full Text] [Related]
49. Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders.
Lee MS; Lee HY; Kang SG; Yang J; Ahn H; Rhee M; Ko YH; Joe SH; Jung IK; Kim SH
J Affect Disord; 2010 Jun; 123(1-3):216-21. PubMed ID: 19914719
[TBL] [Abstract][Full Text] [Related]
50. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
51. Safety of electroconvulsive therapy-duloxetine combination.
Eraslan D; Genc Y; Odabasioglu G; Ergun BM; Ozturk O
J ECT; 2011 Sep; 27(3):e51-2. PubMed ID: 21865952
[No Abstract] [Full Text] [Related]
52. Impact of adherence to antidepressants on healthcare outcomes and costs among patients with type 2 diabetes and comorbid major depressive disorder.
Vega C; Becker RV; Mucha L; Lorenz BH; Eaddy MT; Ogbonnaya AO
Curr Med Res Opin; 2017 Oct; 33(10):1879-1889. PubMed ID: 28644095
[TBL] [Abstract][Full Text] [Related]
53. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
Keyloun KR; Hansen RN; Hepp Z; Gillard P; Thase ME; Devine EB
CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157
[TBL] [Abstract][Full Text] [Related]
54. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis.
Thomas NP; Curkendall S; Farr AM; Yu E; Hurley D
J Med Econ; 2016; 19(5):497-505. PubMed ID: 26706292
[TBL] [Abstract][Full Text] [Related]
55. Evaluating patient adherence to antidepressant therapy among uninsured working adults diagnosed with major depression: results of the Texas Demonstration to Maintain Independence and Employment study.
Nwokeji ED; Bohman TM; Wallisch L; Stoner D; Christensen K; Spence RR; Reed BC; Ostermeyer B
Adm Policy Ment Health; 2012 Sep; 39(5):374-82. PubMed ID: 21553144
[TBL] [Abstract][Full Text] [Related]
56. Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions.
Augendre-Ferrante B; Picard H; Evans D; Arkoub H; Pamulapati S; Perrot S; Valensi P; Rouillon F
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):1-7. PubMed ID: 24161159
[TBL] [Abstract][Full Text] [Related]
57. Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms.
McIntyre RS; Konarski JZ
Expert Opin Pharmacother; 2005 May; 6(5):707-13. PubMed ID: 15934897
[TBL] [Abstract][Full Text] [Related]
58. Average daily dose, medication adherence, and healthcare costs among commercially-insured patients with fibromyalgia treated with duloxetine.
Wu N; Chen S; Boulanger L; Rao P; Zhao Y
Curr Med Res Opin; 2011 Jun; 27(6):1131-9. PubMed ID: 21456939
[TBL] [Abstract][Full Text] [Related]
59. A case of severe hyponatremia induced by duloxetine and ziprasidone.
Li RM; Wang C; Liu ZW; Zhao B
Chin Med J (Engl); 2012 Oct; 125(20):3750-1. PubMed ID: 23075738
[TBL] [Abstract][Full Text] [Related]
60. Atypical Stevens-Johnson syndrome in an adolescent treated with duloxetine.
Strawn JR; Whitsel R; Nandagopal JJ; Delbello MP
J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):91-2. PubMed ID: 21309700
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
